NDA 020457 · Cheplapharm
Etopophos Preservative Free
Etoposide Phosphate · Injection
Last checked: Nov 20, 2026Latest source record: Sep 2, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1996
May 17, 1996
Approved uses
1
Original approval plus efficacy supplements
Registered trials
1,914
435 Phase 3, 235 recruiting
FAERS reports
1,635
1,491 serious, 296 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jul 31, 2026.
ETOPOPHOS is a topoisomerase inhibitor indicated for the treatment of patients with: Refractory testicular tumors, in combination with other chemotherapeutic drugs. ( 1.1 ) Small cell lung cancer, in combination with cisplatin, as first-line treatment. ( 1.2 ) 1.1 Refractory Testicular Tumors ETOPOPHOS is indicated, in combination with other chemotherapeutic drugs, for treatment of patients with refractory testicular tumors. 1.2 Small Cell Lung Cancer ETOPOPHOS is indicated, in combination with cisplatin, for first-line treatment of patients with small cell lung cancer.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- May 17, 1996 Original approval · Type 2 - New Active Ingredient
1 products under this application
- ETOPOPHOS PRESERVATIVE FREE · ETOPOSIDE PHOSPHATE EQ 100MG BASE/VIAL · INJECTABLE, INJECTION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Etoposide" as an intervention, any sponsor and status, largest first.
- International Collaborative Treatment Protocol For Children And Adolescents With Acute Lymphoblastic LeukemiaPivotal-lookingCompleted
University Hospital Schleswig-HolsteinAcademic, hospital or other
NCT01117441 · 6,136 participants · Start Jun 2010 · Primary completion Dec 31, 2021
Drug: PEG-L-asparaginase; cyclophosphamide and 14 more · For: Leukemia
Sites: Randwick, Australia; Westmead, Australia; Dornbirn, Austria · 139 sites in all
- Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive MutationsPivotal-lookingCompleted
National Cancer Institute (NCI)NIH
NCT02883049 · 5,949 participants · Start Feb 29, 2012 · Primary completion Dec 31, 2022
Drug: Clofarabine; Cyclophosphamide and 14 more · For: B Acute Lymphoblastic Leukemia; B Acute Lymphoblastic Leukemia, BCR-ABL1-Like; Central Nervous System Leukemia and 1 more
Sites: Birmingham, Alabama; Mobile, Alabama; Anchorage, Alaska · 239 sites in all
- Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017Pivotal-lookingRecruiting
Martin SchrappeAcademic, hospital or other
NCT03643276 · 5,000 participants (planned) · Start Jul 15, 2018 · Primary completion Jul 14, 2028
Drug: Blinatumomab; Bortezomib and 17 more · For: Acute Lymphoblastic Leukemia, Pediatric
Sites: Sydney, Australia; Westmead, Australia; Graz, Austria · 115 sites in all
- Combination Chemotherapy Based on Risk of Relapse in Treating Young Patients With Acute Lymphoblastic LeukemiaPivotal-lookingCompleted
University Hospital Schleswig-HolsteinAcademic, hospital or other
NCT00430118 · 4,559 participants · Start Jul 2000 · Primary completion Jan 2012
Drug: asparaginase; cyclophosphamide and 12 more · For: Leukemia
Sites: Dornbirn, Austria; Feldkirch-Tisis, Austria; Graz, Austria · 76 sites in all
- Risk-Adjusted Combination Chemotherapy in Treating Young Patients With Acute Lymphoblastic LeukemiaPivotal-lookingStatus unknown
University Hospital, MotolAcademic, hospital or other
NCT00764907 · 4,000 participants (planned) · Start Nov 2002 · Primary completion Oct 2007
Drug: asparaginase; cyclophosphamide and 13 more · For: Leukemia
Sites: Prague, Czechia
- High Risk Neuroblastoma Study 1 of SIOP-Europe (SIOPEN)Pivotal-lookingCompleted
St. Anna KinderkrebsforschungAcademic, hospital or other
NCT01704716 · 3,569 participants · Start Feb 1, 2002 · Primary completion Jan 30, 2025
Drug: Vincristine; Aldesleukin and 9 more · For: Neuroblastoma
Sites: Newcastle, Australia; Sydney, Australia; Vienna, Austria · 122 sites in all
Societe Internationale d'Oncologie PediatriqueAcademic, hospital or other
NCT00276640 · 3,417 participants · Start Apr 1, 2004 · Primary completion Dec 31, 2015
Drug: vincristine, carboplatin; vincristine, carboplatin, etoposide · For: Primary Central Nervous System Neoplasms
Sites: Vienna, Austria; Ghent, Belgium; Zagreb, Croatia · 13 sites in all
- Combination Chemotherapy Compared With No Treatment Following Surgery in Treating Patients With Non-small Cell Lung CancerPivotal-lookingCompleted
Gustave Roussy, Cancer Campus, Grand ParisAcademic, hospital or other
NCT00002823 · 3,300 participants (planned) · Start Feb 1995 · Primary completion Jan 2001
Drug: cisplatin; etoposide and 3 more · For: Lung Cancer
Sites: Atlantis, Florida; Boston, Massachusetts; Buenos Aires, Argentina · 123 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- off label use200
- disease progression163
- product use in unapproved indication93
- acute kidney injury83
- thrombocytopenia82
- febrile neutropenia72
- pyrexia71
- drug ineffective68
- malignant neoplasm progression68
- neutropenia61
- product storage error61
- anaemia59
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 6 |
| 2005 | 4 |
| 2006 | 10 |
| 2007 | 11 |
| 2010 | 3 |
| 2012 | 19 |
| 2013 | 57 |
| 2014 | 52 |
| 2015 | 68 |
| 2016 | 126 |
| 2017 | 86 |
| 2018 | 182 |
| 2019 | 164 |
| 2020 | 95 |
| 2021 | 107 |
| 2022 | 151 |
| 2023 | 188 |
| 2024 | 138 |
| 2025 | 102 |
| 2026 | 66 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial.
Paz-Ares L, Dvorkin M, Chen Y, et al. · Lancet 2019 · Clinical Trial, Phase III, Multicenter Study
- Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial.
Goldman JW, Dvorkin M, Chen Y, et al. · Lancet Oncol 2021 · Clinical Trial, Phase III, Comparative Study
- Five-year survival in patients with extensive-stage small cell lung cancer treated with atezolizumab in the Phase III IMpower133 study and the Phase III IMbrella A extension study.
Reck M, Dziadziuszko R, Sugawara S, et al. · Lung Cancer 2024 · Clinical Trial, Phase III, Randomized Controlled Trial
- Total Body Irradiation or Chemotherapy Conditioning in Childhood ALL: A Multinational, Randomized, Noninferiority Phase III Study.
Peters C, Dalle JH, Locatelli F, et al. · J Clin Oncol 2021 · Clinical Trial, Phase III, Multicenter Study
- Mistletoe Extracts during the Oncological Perioperative Period: A Systematic Review and Meta-Analysis of Human Randomized Controlled Trials.
Cogo E, Elsayed M, Bhardwaj S, et al. · Curr Oncol 2023 · Meta-Analysis, Systematic Review
- Clinical factors of PICC-RVT in cancer patients: a meta-analysis.
Ma S, Shen C, Li Q, et al. · Support Care Cancer 2023 · Systematic Review, Meta-Analysis
Sponsor: Cheplapharm
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.